Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
20 July 2017Website:
http://www.kalarx.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 23:58:49 GMTDividend
Analysts recommendations
Institutional Ownership
KALA Latest News
The mean of analysts' price targets for KALA BIO (KALA) points to a 152.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
KALA BIO (KALA) came out with a quarterly loss of $3.41 per share versus the Zacks Consensus Estimate of a loss of $2.15. This compares to earnings of $19.25 per share a year ago.
The mean of analysts' price targets for Kala Pharma (KALA) points to a 213.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
What type of business is Kala Pharmaceuticals?
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.
What sector is Kala Pharmaceuticals in?
Kala Pharmaceuticals is in the Healthcare sector
What industry is Kala Pharmaceuticals in?
Kala Pharmaceuticals is in the Biotechnology industry
What country is Kala Pharmaceuticals from?
Kala Pharmaceuticals is headquartered in United States
When did Kala Pharmaceuticals go public?
Kala Pharmaceuticals initial public offering (IPO) was on 20 July 2017
What is Kala Pharmaceuticals website?
https://www.kalarx.com
Is Kala Pharmaceuticals in the S&P 500?
No, Kala Pharmaceuticals is not included in the S&P 500 index
Is Kala Pharmaceuticals in the NASDAQ 100?
No, Kala Pharmaceuticals is not included in the NASDAQ 100 index
Is Kala Pharmaceuticals in the Dow Jones?
No, Kala Pharmaceuticals is not included in the Dow Jones index
When does Kala Pharmaceuticals report earnings?
The next expected earnings date for Kala Pharmaceuticals is 02 August 2024